Characteristics of study population according to NPM1 mutation status
| . | All patients . | NPMc+ . | NPMc− . | P . | |||
|---|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | ||
| Total | 295 | 100 | 23 | 7.8 | 272 | 92.2 | |
| FLT3/ITD | .046‡ | ||||||
| Positive | 52 | 19 | 8 | 36 | 44 | 18 | |
| Negative | 218 | 81 | 14 | 64 | 204 | 82 | |
| Sex | .029‡ | ||||||
| Male | 144 | 49 | 6 | 26 | 138 | 51 | |
| Female | 151 | 51 | 17 | 74 | 134 | 49 | |
| Age, y | |||||||
| Median (range) | 9.5 (0-19.5) | 10.9 (3.1-18.8) | 9.4 (0-19.5) | .047‡ | |||
| 0 to younger than 3 | 71 | 24 | 0 | 0 | 71 | 26 | .002‡ |
| 3 to younger than 6 | 30 | 10 | 3 | 13 | 27 | 10 | .716 |
| 6 to younger than 9 | 39 | 13 | 4 | 17 | 35 | 13 | .523 |
| 9 to younger than 12 | 38 | 13 | 6 | 26 | 32 | 12 | .095 |
| 12 to younger than 15 | 60 | 20 | 4 | 17 | 56 | 21 | .999 |
| 15 to younger than 18 | 49 | 17 | 4 | 17 | 45 | 17 | .999 |
| 18 to younger than 21 | 8 | 3 | 2 | 9 | 6 | 2 | .122 |
| WBC, × 109/L, median (range) | 47.7 (1.3-667) | 38.2 (1.6-667) | 49.1 (1.3-633.6) | .942 | |||
| Cytogenetics | |||||||
| Normal | 87 | 29 | 17 | 74 | 70 | 26 | < .001‡ |
| 11q23* | 46 | 16 | 1 | 4 | 45 | 17 | .138 |
| inv(16) | 24 | 8 | 0 | 0 | 24 | 9 | .236 |
| t(8;21) | 26 | 9 | 0 | 0 | 26 | 10 | .142 |
| Miscellaneous† | 69 | 23 | 3 | 13 | 66 | 24 | .206 |
| Failed | 12 | 4 | 1 | 4 | 11 | 4 | .999 |
| Not received | 31 | 11 | 1 | 4 | 30 | 11 | .487 |
| Response to induction chemotherapy | .369 | ||||||
| CR | 248 | 85 | 18 | 78 | 230 | 85 | |
| Not CR | 45 | 15 | 5 | 22 | 40 | 15 | |
| . | All patients . | NPMc+ . | NPMc− . | P . | |||
|---|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | ||
| Total | 295 | 100 | 23 | 7.8 | 272 | 92.2 | |
| FLT3/ITD | .046‡ | ||||||
| Positive | 52 | 19 | 8 | 36 | 44 | 18 | |
| Negative | 218 | 81 | 14 | 64 | 204 | 82 | |
| Sex | .029‡ | ||||||
| Male | 144 | 49 | 6 | 26 | 138 | 51 | |
| Female | 151 | 51 | 17 | 74 | 134 | 49 | |
| Age, y | |||||||
| Median (range) | 9.5 (0-19.5) | 10.9 (3.1-18.8) | 9.4 (0-19.5) | .047‡ | |||
| 0 to younger than 3 | 71 | 24 | 0 | 0 | 71 | 26 | .002‡ |
| 3 to younger than 6 | 30 | 10 | 3 | 13 | 27 | 10 | .716 |
| 6 to younger than 9 | 39 | 13 | 4 | 17 | 35 | 13 | .523 |
| 9 to younger than 12 | 38 | 13 | 6 | 26 | 32 | 12 | .095 |
| 12 to younger than 15 | 60 | 20 | 4 | 17 | 56 | 21 | .999 |
| 15 to younger than 18 | 49 | 17 | 4 | 17 | 45 | 17 | .999 |
| 18 to younger than 21 | 8 | 3 | 2 | 9 | 6 | 2 | .122 |
| WBC, × 109/L, median (range) | 47.7 (1.3-667) | 38.2 (1.6-667) | 49.1 (1.3-633.6) | .942 | |||
| Cytogenetics | |||||||
| Normal | 87 | 29 | 17 | 74 | 70 | 26 | < .001‡ |
| 11q23* | 46 | 16 | 1 | 4 | 45 | 17 | .138 |
| inv(16) | 24 | 8 | 0 | 0 | 24 | 9 | .236 |
| t(8;21) | 26 | 9 | 0 | 0 | 26 | 10 | .142 |
| Miscellaneous† | 69 | 23 | 3 | 13 | 66 | 24 | .206 |
| Failed | 12 | 4 | 1 | 4 | 11 | 4 | .999 |
| Not received | 31 | 11 | 1 | 4 | 30 | 11 | .487 |
| Response to induction chemotherapy | .369 | ||||||
| CR | 248 | 85 | 18 | 78 | 230 | 85 | |
| Not CR | 45 | 15 | 5 | 22 | 40 | 15 | |
Percentages are calculated based on the available data.
NPMc+ indicates positive for NPM1 mutation; NPMc−, negative for NPM1 mutation; FLT3/ITD, internal tandem duplication of FLT3; and WBC, white blood cell count.
The 11q23 category included all cases with translocations involving the MLL gene at 11q23, most of which were t(9;11)(p22;q23), forming the MLL-AF9 fusion.
The miscellaneous category includes patients with cytogenetic abnormalities other than 11q23, inv(16), or t(8;21).
Significant P values.